POR8: MINIMAL STANDARDS FOR THE VALIDATION OF QUALITY OF LIFE INSTRUMENTS USED IN CLINICAL TRIALS  by Chassany, O et al.
Abstracts 219
ing considered on each criterion in the preference struc-
ture; 4) Normalize and average the preferences for each
drug agent; 5) Create a statistic that indicates consistency
in quantifying the preferences; 6) Determine the prefer-
ence of each criterion relative to every other criterion in
the preference structure (normalize, average, and check
consistency); 7) Determine summary preference “score”
for each drug agent; 8) Choose the drug agent having the
greatest summary preference.
RESULTS: The optimal drug identified by the AHP was
the same drug agent identified by the Formulary Steering
Committee for inclusion in the formulary. However, the
AHP achieved this result with a comparable reduction in
inconsistency, greater efficiency and the ability to per-
form a sensitivity analysis of the outcome. 
CONCLUSIONS: The analytical hierarchy process can
be used to successfully identify appropriate drug agents
for formulary placement in managed care settings. Use of
this method allows formulary members to quantify their
subjective preferences among competing drug agents.
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OBJECTIVE: The purpose of the present study was to val-
idate the structural model of the SF-12 with data from the
1990 National Survey of Functional Health Status (NHS). 
METHODS: We used Confirmatory Factor Analytic (CFA)
to evaluate the structure of the MOS SF-12. CFA is ideally
suited for examining self-report survey tools, in that the
proposed structural characteristics are statistically evalu-
ated by comparing the estimated population covariance
matrix, estimated from the proposed parameters, to the
sample covariance matrix. 
RESULTS: There was substantial support for the hypoth-
esized structure of the SF-12; however, it was not a statis-
tically adequate fit (r2  1672.27; fit indices were well
below 0.9 [CFI  0.85]). The model was significantly im-
proved by adding a covariance path between Physical
Health and Mental Health, adding an additional link be-
tween General Mental Health and Physical Health, and the
addition of two covariances among the item errors. This re-
vised structure represented a good fit to the data (r2 
338.26; fit indices were well above 0.9 [CFI  0.97]). This
suggests that there are some commonalties between self-re-
ported Physical and Mental Health. This was supported by
the strong correlation between Physical Health and Mental
Health (r  0.838; 70% shared variance).
CONCLUSION: While there was some support for the
hypothesized structure, there was substantial evidence to
support the dependencies between Physical and Mental
Health. These findings are very similar to our previous
work with the SF-36 that suggests that a substantial por-
tion of these two constructs, Physical and Mental Health,
reflect a common construct. The SF-12 appears to be rel-
atively free of correlated errors, unlike the SF-36, and
may have fewer problems with systematic measurement
error or idiosyncratic interpretation of item content.
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OBJECTIVE: In recent years, a number of primers, stan-
dards, and guidelines have appeared in the pursuit of pro-
moting “good practice” and improving the overall quality
of economic evaluations. However, none of these contain
the logical next step: a scoring system that evaluates and
summarizes the quality of the studies. This research inves-
tigates whether a scoring system can be developed for pub-
lished economic evaluations, and discusses how such a sys-
tem can assist in clearly identifying studies of a better
quality, which in turn would provide the evidence to allow
priorities to be set in a more explicit manner. We construct
a scoring system based on an adaptation of the BMJ
Working Party 35-point checklist, and illustrate its appli-
cation to a case study of schizophrenia. 
METHODS: A comprehensive literature search was con-
ducted for the period 1966–1997. The inclusion criteria
were: 1) the study considered both the costs, and cost or
health consequences of alternative health programs for
schizophrenia; 2) the study was published in English; 3)
the majority (i.e., 50%) of the patients sampled had a
diagnosis of schizophrenia or related psychoses. The
studies were scored according to the maximum total
which could be achieved for each study. Selected items
(e.g., perspective) were given more weighting according
to their importance as determined by a recent survey of
health economists. 
RESULTS: Thirty studies met the inclusion criteria (17
US, 7 UK, 6 elsewhere). The studies either considered al-
ternative methods of service delivery or the use of novel
antipsychotic drugs (e.g., clozapine or risperidone). The
quality scores ranged from 43–88%. 
CONCLUSIONS: It is shown that our scoring approach
may be one reasonable method of summarising method-
ological quality. Further research needs to be performed
on the development of economic quality scoring methods
and the link between the quality of economic information
to their effects on decision-making.
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OBJECTIVES: Quality of life (QoL) is being increasingly
used as a secondary endpoint in clinical trials. The accu-
rate and precise measurement of QoL requires rigorous
scientific attention to the design and validation of ques-
tionnaires. The aim of the present study is to review the
available regulatory and medical literature and to suggest
minimal standards for the validation of QoL instruments. 
METHODS: Existing FDA and EMEA guidelines were
reviewed. A Medline search strategy was developed to
identify and retrieve relevant publications. 
RESULTS: There are currently no regulatory guidelines
from either the FDA or EMEA regarding validation of
QoL instruments. The search strategy identified 238 arti-
cles on instrument validation and 22 review articles on
validation methodologies. There is consensus in the liter-
ature that QoL assessment must be formally validated in
order to be acceptable as scientific evidence of interven-
tion effectiveness. Minimal validation criteria include: 1)
a clear definition of QoL relevant to the studied popula-
tion, 2) documentation of scientific methods used to de-
velop questionnaire instrument(s), 3) demonstration of
the performance of the instrument(s) in terms of accept-
ability, validity, and responsiveness, and 4) documenta-
tion of statistical methods used to derive scales, domains,
and other constructs. 
CONCLUSIONS: A validation study should be performed
prior to incorporating QoL instruments into clinical trials.
Results of these studies should be published in the medical
literature. A validation checklist is proposed to assist regu-
latory bodies in evaluating the quality of QoL instruments
used to support regulatory applications.
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Pharmaceutical manufacturers are spending more than
10% of their annual gross income for research and devel-
opment. Pre-clinical studies take 20% of these expendi-
tures and clinical phases take 40%. But only 5% of the
substances that have passed the pre-clinical phase suc-
cessfully will pass the four clinical phases and be ap-
proved for usage. Such an outcome explains the low sen-
sitivity and selectivity of test-systems using the laboratory
animal as a model of human. These systems are based on
widespread theory of the phylogenetic species continuity
concept which propose that human and animals have the
same sensitivity to the therapeutic and toxic action of
drugs. The biochemical species stability concept is less
known and postulates the essential interspecies and in-
traspecies variability on a biochemical level. According to
this theory, human material (cell cultures and tissues)
should be used as a test-system for drug testing. Clinical
epidemiology is the new fast growth discipline which
gives evidence for using methods of therapy or diagnos-
tics. It has routine procedures for the quantitative estima-
tion of test-systems and characterizes them by sensitivity,
selectivity, and validity. These procedures allow to discard
low effective test-systems. Principles of clinical epidemiol-
ogy can increase successful trials and diminish costs.
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OBJECTIVE: The purpose of this research is to develop a
decision model for evaluating the impact of information
regarding alternative treatments, toxicity, efficacy, deliv-
ery method, and cost on demand for unique compounds. 
METHODS: This paper characterizes the relationship be-
tween multi-attribute utility theory and health-state prefer-
ences. Health outcomes arising from pharmaceutical in-
terventions are viewed as multiattribute commodities.
Presenters describe a method for reliable, utility-theoretic
quantification of health-state preferences. This procedure
requires estimating utility weights from stated-preference
(SP) data. Including health cost as an SP attribute facilitates
conversion of marginal utilities to marginal dollar values
to explicitly account for cost in determining market share.
Additionally, various utility specifications and simplifying
assumptions are described. Finally, a rule for simulating
aggregate choice behavior over time is presented. The pre-
diction rule employed draws upon random utility maximi-
zation with adaptive expectations. This method addresses
the probabilistic nature of the choice process by inclusion
of a residual term representing the effect of unobserved
factors on perceived utility. Expectation updating deals
with imperfect information about product attributes such
as efficacy and side effects by allowing learning to take
place over successive drug administrations. 
RESULTS: A numerical example considering migraine
medications demonstrates the capability of the decision
model. In this example, a general, preference-based form
for health-related utility facilitates direct estimation of
health attribute utility weights arising from pharmaceuti-
cal consumption. Manipulating pharmaceutical attributes
in a random utility framework simulates choice probabili-
ties. Repeatedly simulating choice probabilities with at-
tribute expectation updating provides market penetration
estimates for unique compounds over time. 
CONCLUSIONS: Combining stated preference survey
techniques with random utility and adaptive expectations
provides a unique and realistic method for predicting de-
mand for novel compounds.
